• Sample Page

Targeting the ubiquitin–proteasome system for cancer therapy

3613-73-8 IC50

Androgen receptor splicing variations (ARVs) which absence the ligand-binding area (LBD)

February 12, 2019 by Katherine Lewis Leave a Comment

Androgen receptor splicing variations (ARVs) which absence the ligand-binding area (LBD) are from the advancement of castration-resistant prostate tumor (CRPC), including level of resistance to the brand new era of great affinity anti-androgens. of individual CRPC xenografts. These outcomes indicate that induction ARVs by turned on NF-B signaling in PCa cells is certainly a critical … [Read more…]

Posted in: Blogging Tagged: 3613-73-8 IC50, VEGFA

Copyright © 2026 Targeting the ubiquitin–proteasome system for cancer therapy.

Omega Child WordPress Theme by